-The Hindu Communist Party of India (Marxist) Polit Bureau member Brinda Karat on Wednesday demanded an independent inquiry into the Comptroller and Auditor General (CAG) report, which has pointed out serious lapses and wrongdoings in the Rs. 52,000-crore farm debt waiver scheme. Ms. Karat was talking to journalists at the party office here, before resuming her programme of “Sangharsh Sandesh Jatha,” which began from Jallianwala Bagh in Amritsar on March 4. She said...
More »SEARCH RESULT
Total Matching Records found : 835
Natco Pharma wins cancer drug case-R Sivaraman
-The Hindu Bayer's plea dismissed by the Intellectual Property Appellate Board The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs. Disposing an appeal filed by Bayer...
More »Bayer plea dismissed, Natco allowed to sell patent cancer drug
-The Business Standard Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India. IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to...
More »Budget 2013: Why the Nirbhaya fund is not what the Indian woman needs
-First Post While Finance Minister P Chidambaram played the knight in the shining armour role to the hilt, going all out to woo the Indian woman – with an all-woman bank, the ‘Nirbhaya’ fund and an empathetic lecture on the girl child- after the shock value wears out, we are only left with measures which at best might only scrape the tip of the iceberg that is women’s development and security...
More »'436 killed in clinical trials last year'-Durgesh Nandan Jha
-The Times of India As many as 436 people died last year due to serious adverse events (SAE) during clinical trials. Investigations are now on to ascertain how many of the deaths were caused by drugs administered to the trial subjects. Union health minister Ghulam Nabi Azad said on Friday that deaths could be due to life-threatening diseases such as cancer, heart failure and stroke or side-effects of the drugs or their...
More »
